Alpha-Lipoic Acid (ALA)

Alpha-lipoic acid is one of the few supplements where the strongest evidence sits in a single, well-defined clinical use case: nerve discomfort in diabetic peripheral neuropathy. ALA has been sold as a prescription drug in Germany (Thioctacid) for diabetic neuropathy since the 1960s, and that pharma-grade ecosystem funded the ALADIN trial series (Ziegler 1995, ALADIN II Reljanovic 1999, ALADIN III 1999), the SYDNEY IV trial (Ametov 2003), and the larger oral SYDNEY 2 trial (Ziegler 2006). SYDNEY 2 randomized 181 patients to 600, 1200, 1800mg/day oral ALA or placebo for 5 weeks; all three doses beat placebo on the Total Symptom Score, but 600mg/day produced the best risk-to-benefit ratio because the higher doses introduced more nausea without more benefit. That 600mg/day finding is the source of essentially every modern ALA neuropathy dosing recommendation.

The NATHAN 1 trial (Ziegler 2011) is the longest and largest. 460 patients with mild-to-moderate diabetic distal symmetric polyneuropathy, 4 years of 600mg/day oral ALA vs placebo. The primary composite endpoint (NIS-LL plus seven neurophysiologic tests) did not reach significance, but a clinically meaningful improvement and prevention of progression of neuropathic impairments showed up on prespecified subscales, with good tolerability. The 2024 Cochrane review by Baicus restricted analysis to RCTs of at least 6 months and concluded ALA "probably has little or no effect on symptoms of diabetic peripheral neuropathy and may have little or no effect on impairment after six months." Reasonable people read the same dataset differently: shorter, higher-quality symptomatic trials look positive; longer trials with hard endpoints look modest.

The weight-loss signal is real but small. Namazi 2018 (Clinical Nutrition, 12 trials) found a statistically significant reduction in body weight (about 1.27kg, 95% CI -2.20 to -0.34) and BMI on pooled analysis, mostly at 300-1800mg/day for 8-24 weeks. A 2020 update by Kucukgoncu confirmed the direction. Magnitude is roughly one kg over a few months — modest, not transformative, and considerably less than GLP-1 agonists or even consistent caloric restriction.

The general-antioxidant story is the messiest. Mechanism is impeccable: ALA recycles glutathione, vitamin C, and vitamin E, the dihydrolipoic acid (DHLA) reduced form is regenerated, and the molecule is both water- and fat-soluble. Functional outcomes in healthy adults — energy, longevity, cognition, glycemic control in non-diabetics — have not produced clean replicated RCTs. Treat the "universal antioxidant" framing as biochemically true but clinically underwhelming outside the diabetic neuropathy and modest weight signals.

Form matters more than for almost any other supplement here. Racemic ALA is unstable, polymerizes with heat, and the S enantiomer is essentially inert in mitochondrial metabolism. Hermann 1996 showed the R enantiomer reaches plasma concentrations 40-50% higher than S after an oral racemic dose; Carlson 2007 demonstrated that the sodium salt of R-ALA (Na-RALA) achieves Cmax values 10-25 times higher than free R-ALA in healthy volunteers. The retail decision lever is whether to pay 2-3x more for Na-RALA's superior PK or take advantage of the trial-validated 600mg/day racemic dose at a fraction of the price.

Safety footnote that matters: ALA has a mild insulin-like glucose-lowering effect, and rare but documented insulin autoimmune syndrome (Hirata disease) has been reported in HLA-DRB1*04:03 carriers — first described in Japanese patients (Yamasaki and others, mid-2000s onward) and confirmed in European Caucasians by Gullo 2014. Patients on insulin or oral hypoglycemics need physician supervision before adding ALA.

Practical bottom line: 600mg/day racemic ALA for 5-12 weeks is reasonable for adults with diabetic peripheral neuropathy under physician care, with the caveat that the Cochrane review tempers expectations for longer-term hard endpoints. Na-RALA at 200-300mg/day is the better-absorbed, premium-priced alternative. Standard antioxidant supplementation in healthy adults is mechanistically defensible but lacks clean outcome data. Anyone on insulin or sulfonylureas should loop in their doctor before starting.